Understanding how bladder cancer cells resist platinum chemotherapy
Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer
This study is looking into how bladder cancer cells become resistant to a common chemotherapy treatment, with the goal of finding new ways to help improve outcomes for patients battling this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11036376 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which bladder cancer cells develop resistance to platinum-based chemotherapy, a common treatment for muscle-invasive and metastatic bladder cancer. The team will use advanced laboratory models and patient-derived data to explore how changes in the cancer cells and their interactions with immune cells contribute to this resistance. By analyzing these cellular processes, the research aims to identify potential targets for improving treatment outcomes for patients with bladder cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with muscle-invasive or metastatic bladder cancer who are undergoing platinum-based chemotherapy.
Not a fit: Patients with non-muscle invasive bladder cancer or those who are not receiving platinum-based chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for bladder cancer patients who currently do not respond well to platinum chemotherapy.
How similar studies have performed: Previous research has shown promising results in understanding cancer resistance mechanisms, indicating that this approach has the potential for success.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Van Allen, Eliezer M — Dana-Farber Cancer Inst
- Study coordinator: Van Allen, Eliezer M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.